Skip to main content

Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker.

Copaxone (glatiramer acetate) is a blockbuster drug for the treatment of multiple sclerosis, created by Yeda Research and Development Co Ltd. The patents that cover Copaxone, including the process for its preparation, have been extensively litigated around the globe, and in India the patent for the preparation of Copaxone expires on May 23, 2015. For this process patent, several proceedings are currently pending before various bodies in India, including the Delhi High Court, the Intellectual Property Appellate Board and the Indian Patent Office (IPO).

The battle in India began in 2007, when Teva Pharmaceutical Limited, the exclusive licensee of Yeda, initiated infringement proceedings against Natco Pharma Ltd, a generics company based in Hyderabad. Mylan, a US-based pharmaceutical company, is the partner of Natco for Copaxone. While the infringement proceedings were pending, Mylan Pharmaceuticals filed a review petition in November 2013 under Section 77 of the Indian Patents Act before the IPO, challenging the term of the patent granted by the Indian process patent 190759 which was granted on May 15, 2004.

Read more on Life Sciences Intellectual Property Review (requires subscription).

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
•
Nov 14, 2026

Generative artificial intelligence systems are trained on large volumes of information, including text, images, news articles and other digital material.

Can AI Training Be Copyright Infringement? The ANI v. OpenAI Dispute in India
News & Updates, Thought Leadership
•
Nov 11, 2026

Think about the apps you use every day. Their visual identity is often the first thing you recognise: the arrangement of icons, navigation menus, buttons,

Can You Patent the Look of an App? GUI and Icon Protection in India
News & Updates, Thought Leadership
•
Nov 09, 2026

‘First published on Chambers’ By: Dhruv Anand, Dhananjay Khanna and Bhavya Verma It will not be an exaggeration to say that there has been an explosion

PERSONALITY RIGHTS – CURRENT TRENDS
News & Updates, Thought Leadership
•
Nov 09, 2026

‘First published on India Business Law Journal’ By: Shantanu Sahay and Pratyush Acharya As India moved towards full implementation of the Digital Personal

Treatment of legacy personal data under the DPDPA